ELI-002-102

· Elicio Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ELI-002-102, covering 2026-03-17 to 2026-03-17. Get the full timeline:

Most recent: Clinical Trial Update: Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma